STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress

Posted on by

Data demonstrates pharmacological inhibition of METTL1 inhibits tumour growth and reduces tRNA methylation and stability of tRNAs CAMBRIDGE, England, Feb. 22, 2024 /PRNewswire/ — STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.